Epi­ge­net­ic edit­ing start­up Chro­ma lays off staff, fo­cus­ing on reach­ing the clin­ic

Chro­ma Med­i­cine laid off an undis­closed num­ber of em­ploy­ees ear­li­er this week, as the pri­vate­ly held start­up fo­cus­es its re­sources on mov­ing its first epi­ge­net­ic ed­i­tors in­to hu­man test­ing.

The Boston-based biotech is de­vel­op­ing drugs that change gene ex­pres­sion, by adding or re­mov­ing methyl groups, rather than changes to DNA like typ­i­cal gene-edit­ing ef­forts. Af­ter pub­licly launch­ing in 2021, Chro­ma has raised over $250 mil­lion, in­clud­ing a $135 mil­lion Se­ries B an­nounced last March.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER